幹細胞治療市場Stem Cell Therapies Market 幹細胞は未分化な生物学的細胞であり、あらゆる種類の細胞に分裂する可能性を持っている。幹細胞が分裂すると、それぞれの新しい細胞は新しい幹細胞になるか、あるいは筋肉細胞、赤血球、脳細胞など、特定の機能... もっと見る
日本語のページは自動翻訳を利用し作成しています。
サマリー幹細胞は未分化な生物学的細胞であり、あらゆる種類の細胞に分裂する可能性を持っている。幹細胞が分裂すると、それぞれの新しい細胞は新しい幹細胞になるか、あるいは筋肉細胞、赤血球、脳細胞など、特定の機能を持つ別の細胞のようになる。幹細胞には2種類ある。 胚性細胞 成体幹細胞 出生直後の臍帯血から採取される幹細胞。この細胞は特定の条件下で保存することができる。幹細胞は骨髄や脂肪組織からも採取できる。 胚細胞は発生段階で外胚葉、内胚葉、中胚葉に分化することができる。幹細胞は、生体や細胞、組織の再生のための治療や手術に使用される。 幹細胞は、胃腸疾患、代謝性疾患、免疫系疾患、中枢神経系疾患、心血管系疾患、創傷および損傷、眼疾患、筋骨格系疾患の治療に使用される。 成体細胞の採取は胚細胞に比べてやや難しい。なぜなら、成体細胞は自分の体内に存在し、採取がやや困難だからである。 幹細胞治療市場:促進要因と抑制要因 医療における技術の進歩は、今や生命を脅かす病気を治療し、有望な結果をもたらしている。幹細胞治療には、他の細胞や身体の器官を再生させるなど、非常に多くの利点がある。これがこの市場の主な促進要因である。これらの治療法は、多くの生命を脅かす治療に役立っている。疾患の有病率の増加が幹細胞治療市場を牽引しており、医療における技術の進歩も市場を牽引している。医療における技術の進歩は、今や人々を生命を脅かす合併症から救っている。 また、政府や民間団体からの資金提供の増加や、幹細胞療法に注力する企業の増加も市場を牽引している。 しかし、胚性幹細胞を採取するのは簡単だが、成体幹細胞や体性幹細胞を採取するのは難しく、採取した幹細胞を保存するためにはより多くの注意を払わなければならない。 幹細胞治療市場セグメンテーション 幹細胞治療は以下のタイプに分類される。 治療法に基づく 同種幹細胞治療 自家幹細胞治療 用途別 胃腸疾患 代謝疾患 免疫系疾患 中枢神経系疾患 循環器系疾患 傷と怪我 眼疾患 筋骨格系疾患 エンドユーザー別 病院 外来手術センター 幹細胞治療市場概要 医療における急速な技術的優位性とその有望な成果により、幹細胞治療の利用は増加し、予測期間(2015-2025年)には2桁成長が見込まれる。 幹細胞治療市場地域別展望 地理的地域によって、世界の幹細胞治療市場は7つの主要地域に区分される:北米、南米、東欧、西欧、日本を除くアジア太平洋地域、日本、中東・アフリカ。 北米は先進国であり、医療技術も発達しており、人々の医療に対する意識も高い。アジア太平洋地域では、中国とインドがヘルスケアセットアップで急成長している。ヨーロッパもこの市場で良好な成長を見せている。 幹細胞治療市場主要プレイヤー この市場における主なプレーヤーは以下の通りである。 メソブラスト社 ロズリン・セルズ Regeneus Ltd、 ReNeuron Group plc、 インターナショナル・ステム・セル・コーポレーション この調査レポートは、市場の包括的な評価を提示し、思慮深い洞察、事実、過去のデータ、統計的に裏付けられた、業界で検証された市場データを含んでいます。また、適切な仮定と方法論を用いた予測も含まれています。この調査レポートは、市場セグメント、地域、タイプ、技術、用途などのカテゴリー別に分析と情報を提供しています。 本レポートでは、以下の項目について網羅的に分析しています: 市場セグメント 市場ダイナミクス 市場規模 需要と供給 現在のトレンド/問題/課題 競合・参入企業 テクノロジー バリューチェーン 地域分析 北米(米国、カナダ) 中南米(メキシコ、ブラジル) 西欧(ドイツ、イタリア、フランス、イギリス、スペイン、北欧諸国、ベルギー、オランダ、ルクセンブルク) 東欧(ポーランド、ロシア) アジア太平洋(中国、インド、ASEAN、オーストラリア、ニュージーランド) 日本 中東・アフリカ(GCC、南アフリカ、北アフリカ) 本レポートは、業界アナリストによる生の情報、質的・量的評価、業界専門家およびバリューチェーン全体にわたる業界参加者からのインプットをまとめたものです。本レポートでは、親市場の動向、マクロ経済指標、支配要因について、セグメントごとの市場魅力とともに詳細に分析しています。また、様々な市場要因が市場セグメントや地域に与える定性的な影響もマッピングしています。 レポートのハイライト 親市場の詳細な概要 業界における市場ダイナミクスの変化 詳細な市場セグメンテーション 過去、現在、そして予測される市場規模(数量ベース、金額ベース 最近の業界動向と発展 競合他社の状況 主要企業の戦略と提供製品 潜在的かつニッチなセグメント、有望な成長を示す地理的地域 市場パフォーマンスに関する中立的な視点 市場関係者が市場での足跡を維持・強化するための必携情報 注 - レポートに記載されている事実、意見、分析はすべて各アナリストのものです。これらは必ずしもFuture Market Insightsの正式な立場や見解を反映するものではありません。 目次1. Executive Summary1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2017-2021 and Forecast, 2022-2032 4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021 4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Therapy Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Mn) Analysis By Therapy Type, 2017-2021 5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Therapy Type, 2022-2032 5.3.1. Allogeneic Therapy 5.3.2. Autologous Therapy 5.4. Y-o-Y Growth Trend Analysis By Therapy Type, 2017-2021 5.5. Absolute $ Opportunity Analysis By Therapy Type, 2022-2032 Deep-dive segmentation will be available in the sample on request 6. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Indication 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Mn) Analysis By Indication, 2017-2021 6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Indication, 2022-2032 6.3.1. Autoimmune Diseases 6.3.2. Musculoskeletal Disorders 6.3.3. Acute Graft Host Disease 6.3.4. Trauma Injuries 6.3.5. Others 6.4. Y-o-Y Growth Trend Analysis By Indication, 2017-2021 6.5. Absolute $ Opportunity Analysis By Indication, 2022-2032 Deep-dive segmentation will be available in the sample on request 7. Global Market Analysis 2017-2021 and Forecast 2022-2032, By End User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Mn) Analysis By End User, 2017-2021 7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End User, 2022-2032 7.3.1. Hospitals 7.3.2. Acute Care Facilities 7.3.3. Specialized Clinics 7.4. Y-o-Y Growth Trend Analysis By End User, 2017-2021 7.5. Absolute $ Opportunity Analysis By End User, 2022-2032 Deep-dive segmentation will be available in the sample on request 8. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Stem Cell Type 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Mn) Analysis By Stem Cell Type, 2017-2021 8.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Stem Cell Type, 2022-2032 8.3.1. Embryonic Stem Cells 8.3.2. Tissue-specific Stem Cells 8.3.3. Mesenchymal Stem Cells 8.3.4. Induced Pluripotent Stem Cells 8.4. Y-o-Y Growth Trend Analysis By Stem Cell Type, 2017-2021 8.5. Absolute $ Opportunity Analysis By Stem Cell Type, 2022-2032 Deep-dive segmentation will be available in the sample on request 9. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Region 9.1. Introduction 9.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021 9.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032 9.3.1. North America 9.3.2. Latin America 9.3.3. Europe 9.3.4. East Asia 9.3.5. South Asia & Pacific 9.3.6. MEA 9.4. Market Attractiveness Analysis By Region 10. North America Market Analysis 2017-2021 and Forecast 2022-2032, By Country 10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 10.2.1. By Country 10.2.1.1. U.K. 10.2.1.2. Canada 10.2.2. By Therapy Type 10.2.3. By Indication 10.2.4. By End User 10.2.5. By Stem Cell Type 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Therapy Type 10.3.3. By Indication 10.3.4. By End User 10.3.5. By Stem Cell Type 10.4. Key Takeaways 11. Latin America Market Analysis 2017-2021 and Forecast 2022-2032, By Country 11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 11.2.1. By Country 11.2.1.1. Brazil 11.2.1.2. Mexico 11.2.1.3. Rest of Latin America 11.2.2. By Therapy Type 11.2.3. By Indication 11.2.4. By End User 11.2.5. By Stem Cell Type 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Therapy Type 11.3.3. By Indication 11.3.4. By End User 11.3.5. By Stem Cell Type 11.4. Key Takeaways 12. Europe Market Analysis 2017-2021 and Forecast 2022-2032, By Country 12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 12.2.1. By Country 12.2.1.1. Germany 12.2.1.2. U.K. 12.2.1.3. France 12.2.1.4. Spain 12.2.1.5. Italy 12.2.1.6. Rest of Europe 12.2.2. By Therapy Type 12.2.3. By Indication 12.2.4. By End User 12.2.5. By Stem Cell Type 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Therapy Type 12.3.3. By Indication 12.3.4. By End User 12.3.5. By Stem Cell Type 12.4. Key Takeaways 13. East Asia Market Analysis 2017-2021 and Forecast 2022-2032, By Country 13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Therapy Type 13.2.3. By Indication 13.2.4. By End User 13.2.5. By Stem Cell Type 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Therapy Type 13.3.3. By Indication 13.3.4. By End User 13.3.5. By Stem Cell Type 13.4. Key Takeaways 14. South Asia & Pacific Market Analysis 2017-2021 and Forecast 2022-2032, By Country 14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 14.2.1. By Country 14.2.1.1. India 14.2.1.2. Thailand 14.2.1.3. Indonesia 14.2.1.4. Malaysia 14.2.1.5. Singapore 14.2.1.6. Australia 14.2.1.7. New Zealand 14.2.1.8. Rest of South Asia & Pacific 14.2.2. By Therapy Type 14.2.3. By Indication 14.2.4. By End User 14.2.5. By Stem Cell Type 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Therapy Type 14.3.3. By Indication 14.3.4. By End User 14.3.5. By Stem Cell Type 14.4. Key Takeaways 15. MEA Market Analysis 2017-2021 and Forecast 2022-2032, By Country 15.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 15.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Therapy Type 15.2.3. By Indication 15.2.4. By End User 15.2.5. By Stem Cell Type 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Therapy Type 15.3.3. By Indication 15.3.4. By End User 15.3.5. By Stem Cell Type 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. U.K. 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2021 16.1.2.1. By Therapy Type 16.1.2.2. By Indication 16.1.2.3. By End User 16.1.2.4. By Stem Cell Type 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2021 16.2.2.1. By Therapy Type 16.2.2.2. By Indication 16.2.2.3. By End User 16.2.2.4. By Stem Cell Type 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2021 16.3.2.1. By Therapy Type 16.3.2.2. By Indication 16.3.2.3. By End User 16.3.2.4. By Stem Cell Type 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2021 16.4.2.1. By Therapy Type 16.4.2.2. By Indication 16.4.2.3. By End User 16.4.2.4. By Stem Cell Type 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2021 16.5.2.1. By Therapy Type 16.5.2.2. By Indication 16.5.2.3. By End User 16.5.2.4. By Stem Cell Type 16.6. U.K. 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2021 16.6.2.1. By Therapy Type 16.6.2.2. By Indication 16.6.2.3. By End User 16.6.2.4. By Stem Cell Type 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2021 16.7.2.1. By Therapy Type 16.7.2.2. By Indication 16.7.2.3. By End User 16.7.2.4. By Stem Cell Type 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2021 16.8.2.1. By Therapy Type 16.8.2.2. By Indication 16.8.2.3. By End User 16.8.2.4. By Stem Cell Type 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2021 16.9.2.1. By Therapy Type 16.9.2.2. By Indication 16.9.2.3. By End User 16.9.2.4. By Stem Cell Type 16.10. China 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2021 16.10.2.1. By Therapy Type 16.10.2.2. By Indication 16.10.2.3. By End User 16.10.2.4. By Stem Cell Type 16.11. Japan 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2021 16.11.2.1. By Therapy Type 16.11.2.2. By Indication 16.11.2.3. By End User 16.11.2.4. By Stem Cell Type 16.12. South Korea 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2021 16.12.2.1. By Therapy Type 16.12.2.2. By Indication 16.12.2.3. By End User 16.12.2.4. By Stem Cell Type 16.13. India 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2021 16.13.2.1. By Therapy Type 16.13.2.2. By Indication 16.13.2.3. By End User 16.13.2.4. By Stem Cell Type 16.14. Thailand 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2021 16.14.2.1. By Therapy Type 16.14.2.2. By Indication 16.14.2.3. By End User 16.14.2.4. By Stem Cell Type 16.15. Indonesia 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2021 16.15.2.1. By Therapy Type 16.15.2.2. By Indication 16.15.2.3. By End User 16.15.2.4. By Stem Cell Type 16.16. Malaysia 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2021 16.16.2.1. By Therapy Type 16.16.2.2. By Indication 16.16.2.3. By End User 16.16.2.4. By Stem Cell Type 16.17. Singapore 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2021 16.17.2.1. By Therapy Type 16.17.2.2. By Indication 16.17.2.3. By End User 16.17.2.4. By Stem Cell Type 16.18. Australia 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2021 16.18.2.1. By Therapy Type 16.18.2.2. By Indication 16.18.2.3. By End User 16.18.2.4. By Stem Cell Type 16.19. New Zealand 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2021 16.19.2.1. By Therapy Type 16.19.2.2. By Indication 16.19.2.3. By End User 16.19.2.4. By Stem Cell Type 16.20. GCC Countries 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2021 16.20.2.1. By Therapy Type 16.20.2.2. By Indication 16.20.2.3. By End User 16.20.2.4. By Stem Cell Type 16.21. South Africa 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2021 16.21.2.1. By Therapy Type 16.21.2.2. By Indication 16.21.2.3. By End User 16.21.2.4. By Stem Cell Type 16.22. Israel 16.22.1. Pricing Analysis 16.22.2. Market Share Analysis, 2021 16.22.2.1. By Therapy Type 16.22.2.2. By Indication 16.22.2.3. By End User 16.22.2.4. By Stem Cell Type 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Therapy Type 17.3.3. By Indication 17.3.4. By End User 17.3.5. By Stem Cell Type 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Vericel Corporation 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Cyagen Biosciences, Inc. 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Stemcell Technologies Inc. 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Celegene Corporation 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Cellular Dynamics International 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Cytori Therapeutics, Inc. 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Fibrocell Science, Inc. 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Mesoblast Ltd 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Regeneus Ltd 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. EMD Millipore Corporation 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 18.1.11. ReNeuron Group plc 18.1.11.1. Overview 18.1.11.2. Product Portfolio 18.1.11.3. Profitability by Market Segments 18.1.11.4. Sales Footprint 18.1.11.5. Strategy Overview 18.1.11.5.1. Marketing Strategy 18.1.12. International Stem Cell Corporation 18.1.12.1. Overview 18.1.12.2. Product Portfolio 18.1.12.3. Profitability by Market Segments 18.1.12.4. Sales Footprint 18.1.12.5. Strategy Overview 18.1.12.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
SummaryStem cells are undifferentiated biological cells, and having remarkable potential to divide into any kind of other cells. When a stem cell divides, each new cell will be a new stem cell or it will be like another cell which is having specific function such as a muscle cell, a red blood cell, brain cell and some other cells. Table of Contents1. Executive Summary1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2017-2021 and Forecast, 2022-2032 4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021 4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Therapy Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Mn) Analysis By Therapy Type, 2017-2021 5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Therapy Type, 2022-2032 5.3.1. Allogeneic Therapy 5.3.2. Autologous Therapy 5.4. Y-o-Y Growth Trend Analysis By Therapy Type, 2017-2021 5.5. Absolute $ Opportunity Analysis By Therapy Type, 2022-2032 Deep-dive segmentation will be available in the sample on request 6. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Indication 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Mn) Analysis By Indication, 2017-2021 6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Indication, 2022-2032 6.3.1. Autoimmune Diseases 6.3.2. Musculoskeletal Disorders 6.3.3. Acute Graft Host Disease 6.3.4. Trauma Injuries 6.3.5. Others 6.4. Y-o-Y Growth Trend Analysis By Indication, 2017-2021 6.5. Absolute $ Opportunity Analysis By Indication, 2022-2032 Deep-dive segmentation will be available in the sample on request 7. Global Market Analysis 2017-2021 and Forecast 2022-2032, By End User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Mn) Analysis By End User, 2017-2021 7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End User, 2022-2032 7.3.1. Hospitals 7.3.2. Acute Care Facilities 7.3.3. Specialized Clinics 7.4. Y-o-Y Growth Trend Analysis By End User, 2017-2021 7.5. Absolute $ Opportunity Analysis By End User, 2022-2032 Deep-dive segmentation will be available in the sample on request 8. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Stem Cell Type 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Mn) Analysis By Stem Cell Type, 2017-2021 8.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Stem Cell Type, 2022-2032 8.3.1. Embryonic Stem Cells 8.3.2. Tissue-specific Stem Cells 8.3.3. Mesenchymal Stem Cells 8.3.4. Induced Pluripotent Stem Cells 8.4. Y-o-Y Growth Trend Analysis By Stem Cell Type, 2017-2021 8.5. Absolute $ Opportunity Analysis By Stem Cell Type, 2022-2032 Deep-dive segmentation will be available in the sample on request 9. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Region 9.1. Introduction 9.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021 9.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032 9.3.1. North America 9.3.2. Latin America 9.3.3. Europe 9.3.4. East Asia 9.3.5. South Asia & Pacific 9.3.6. MEA 9.4. Market Attractiveness Analysis By Region 10. North America Market Analysis 2017-2021 and Forecast 2022-2032, By Country 10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 10.2.1. By Country 10.2.1.1. U.K. 10.2.1.2. Canada 10.2.2. By Therapy Type 10.2.3. By Indication 10.2.4. By End User 10.2.5. By Stem Cell Type 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Therapy Type 10.3.3. By Indication 10.3.4. By End User 10.3.5. By Stem Cell Type 10.4. Key Takeaways 11. Latin America Market Analysis 2017-2021 and Forecast 2022-2032, By Country 11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 11.2.1. By Country 11.2.1.1. Brazil 11.2.1.2. Mexico 11.2.1.3. Rest of Latin America 11.2.2. By Therapy Type 11.2.3. By Indication 11.2.4. By End User 11.2.5. By Stem Cell Type 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Therapy Type 11.3.3. By Indication 11.3.4. By End User 11.3.5. By Stem Cell Type 11.4. Key Takeaways 12. Europe Market Analysis 2017-2021 and Forecast 2022-2032, By Country 12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 12.2.1. By Country 12.2.1.1. Germany 12.2.1.2. U.K. 12.2.1.3. France 12.2.1.4. Spain 12.2.1.5. Italy 12.2.1.6. Rest of Europe 12.2.2. By Therapy Type 12.2.3. By Indication 12.2.4. By End User 12.2.5. By Stem Cell Type 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Therapy Type 12.3.3. By Indication 12.3.4. By End User 12.3.5. By Stem Cell Type 12.4. Key Takeaways 13. East Asia Market Analysis 2017-2021 and Forecast 2022-2032, By Country 13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Therapy Type 13.2.3. By Indication 13.2.4. By End User 13.2.5. By Stem Cell Type 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Therapy Type 13.3.3. By Indication 13.3.4. By End User 13.3.5. By Stem Cell Type 13.4. Key Takeaways 14. South Asia & Pacific Market Analysis 2017-2021 and Forecast 2022-2032, By Country 14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 14.2.1. By Country 14.2.1.1. India 14.2.1.2. Thailand 14.2.1.3. Indonesia 14.2.1.4. Malaysia 14.2.1.5. Singapore 14.2.1.6. Australia 14.2.1.7. New Zealand 14.2.1.8. Rest of South Asia & Pacific 14.2.2. By Therapy Type 14.2.3. By Indication 14.2.4. By End User 14.2.5. By Stem Cell Type 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Therapy Type 14.3.3. By Indication 14.3.4. By End User 14.3.5. By Stem Cell Type 14.4. Key Takeaways 15. MEA Market Analysis 2017-2021 and Forecast 2022-2032, By Country 15.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 15.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Therapy Type 15.2.3. By Indication 15.2.4. By End User 15.2.5. By Stem Cell Type 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Therapy Type 15.3.3. By Indication 15.3.4. By End User 15.3.5. By Stem Cell Type 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. U.K. 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2021 16.1.2.1. By Therapy Type 16.1.2.2. By Indication 16.1.2.3. By End User 16.1.2.4. By Stem Cell Type 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2021 16.2.2.1. By Therapy Type 16.2.2.2. By Indication 16.2.2.3. By End User 16.2.2.4. By Stem Cell Type 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2021 16.3.2.1. By Therapy Type 16.3.2.2. By Indication 16.3.2.3. By End User 16.3.2.4. By Stem Cell Type 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2021 16.4.2.1. By Therapy Type 16.4.2.2. By Indication 16.4.2.3. By End User 16.4.2.4. By Stem Cell Type 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2021 16.5.2.1. By Therapy Type 16.5.2.2. By Indication 16.5.2.3. By End User 16.5.2.4. By Stem Cell Type 16.6. U.K. 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2021 16.6.2.1. By Therapy Type 16.6.2.2. By Indication 16.6.2.3. By End User 16.6.2.4. By Stem Cell Type 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2021 16.7.2.1. By Therapy Type 16.7.2.2. By Indication 16.7.2.3. By End User 16.7.2.4. By Stem Cell Type 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2021 16.8.2.1. By Therapy Type 16.8.2.2. By Indication 16.8.2.3. By End User 16.8.2.4. By Stem Cell Type 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2021 16.9.2.1. By Therapy Type 16.9.2.2. By Indication 16.9.2.3. By End User 16.9.2.4. By Stem Cell Type 16.10. China 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2021 16.10.2.1. By Therapy Type 16.10.2.2. By Indication 16.10.2.3. By End User 16.10.2.4. By Stem Cell Type 16.11. Japan 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2021 16.11.2.1. By Therapy Type 16.11.2.2. By Indication 16.11.2.3. By End User 16.11.2.4. By Stem Cell Type 16.12. South Korea 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2021 16.12.2.1. By Therapy Type 16.12.2.2. By Indication 16.12.2.3. By End User 16.12.2.4. By Stem Cell Type 16.13. India 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2021 16.13.2.1. By Therapy Type 16.13.2.2. By Indication 16.13.2.3. By End User 16.13.2.4. By Stem Cell Type 16.14. Thailand 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2021 16.14.2.1. By Therapy Type 16.14.2.2. By Indication 16.14.2.3. By End User 16.14.2.4. By Stem Cell Type 16.15. Indonesia 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2021 16.15.2.1. By Therapy Type 16.15.2.2. By Indication 16.15.2.3. By End User 16.15.2.4. By Stem Cell Type 16.16. Malaysia 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2021 16.16.2.1. By Therapy Type 16.16.2.2. By Indication 16.16.2.3. By End User 16.16.2.4. By Stem Cell Type 16.17. Singapore 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2021 16.17.2.1. By Therapy Type 16.17.2.2. By Indication 16.17.2.3. By End User 16.17.2.4. By Stem Cell Type 16.18. Australia 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2021 16.18.2.1. By Therapy Type 16.18.2.2. By Indication 16.18.2.3. By End User 16.18.2.4. By Stem Cell Type 16.19. New Zealand 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2021 16.19.2.1. By Therapy Type 16.19.2.2. By Indication 16.19.2.3. By End User 16.19.2.4. By Stem Cell Type 16.20. GCC Countries 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2021 16.20.2.1. By Therapy Type 16.20.2.2. By Indication 16.20.2.3. By End User 16.20.2.4. By Stem Cell Type 16.21. South Africa 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2021 16.21.2.1. By Therapy Type 16.21.2.2. By Indication 16.21.2.3. By End User 16.21.2.4. By Stem Cell Type 16.22. Israel 16.22.1. Pricing Analysis 16.22.2. Market Share Analysis, 2021 16.22.2.1. By Therapy Type 16.22.2.2. By Indication 16.22.2.3. By End User 16.22.2.4. By Stem Cell Type 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Therapy Type 17.3.3. By Indication 17.3.4. By End User 17.3.5. By Stem Cell Type 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Vericel Corporation 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Cyagen Biosciences, Inc. 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Stemcell Technologies Inc. 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Celegene Corporation 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Cellular Dynamics International 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Cytori Therapeutics, Inc. 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Fibrocell Science, Inc. 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Mesoblast Ltd 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Regeneus Ltd 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. EMD Millipore Corporation 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 18.1.11. ReNeuron Group plc 18.1.11.1. Overview 18.1.11.2. Product Portfolio 18.1.11.3. Profitability by Market Segments 18.1.11.4. Sales Footprint 18.1.11.5. Strategy Overview 18.1.11.5.1. Marketing Strategy 18.1.12. International Stem Cell Corporation 18.1.12.1. Overview 18.1.12.2. Product Portfolio 18.1.12.3. Profitability by Market Segments 18.1.12.4. Sales Footprint 18.1.12.5. Strategy Overview 18.1.12.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療)の最新刊レポートFuture Market Insights社の医療・製薬・メディカルデバイス分野での最新刊レポート本レポートと同じKEY WORD(stem cell)の最新刊レポートよくあるご質問Future Market Insights社はどのような調査会社ですか?Future Market Insights(FMI)は世界の広範な地域および産業を対象にした調査レポートを出版しています。 弊社ウェブサイトに掲載のないタイトルも全てお取り扱い可能ですので... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/15 10:26 157.84 円 166.62 円 202.61 円 |